Markets by

The tender offer values Recordati at €51.29 a share, 13% above its price before a CVC takeover approach was disclosed in March

Posted May 26, 2026 4:15AM ET

CVC Capital Partners has announced a significant venture, teaming up with Global Buyout Leaders (GBL) in a bold $12.5 billion bid to take Recordati S.p.A., a leading pharmaceutical company, private. This strategic move is poised to reshape the pharmaceutical landscape, offering potential for enhanced growth and innovation under private ownership.

The collaboration between CVC and GBL reflects a growing trend in the industry where investment firms seek to capitalize on the long-term opportunities within established pharmaceutical entities. Recordati, known for its specialty medicines and market presence in Europe and beyond, stands to benefit from this partnership, unlocking new avenues for development and expansion.

As this acquisition unfolds, stakeholders will be keenly watching how the integration of CVC’s investment prowess and GBL’s strategic insights will drive Recordati’s vision forward, especially in a rapidly evolving market. This deal not only signifies a commitment to advancing the company’s capabilities but also underlines the robust investor confidence in the pharmaceutical sector’s future.

Breaking news on Recordati acquisition by CVC displayed on a large screen with a person holding a Financial Times newspaper showing the same headline. — Breaking news highlights CVC’s €3.2 billion acquisition of Recordati in a bustling London street scene.

CVC Teams Up With GBL for $12.5 Billion Bid to Take Recordati Private

CVC Capital Partners has made headlines with its ambitious plan to take Recordati S.p.A., a prominent pharmaceutical company, private in a joint venture with Global Buyout Leaders (GBL). This bold move, valued at $12.5 billion, is expected to significantly impact the pharmaceutical landscape, driving growth and innovation under private ownership.

Valuation of Recordati

The tender offer values Recordati at €51.29 per share, representing a 13% premium over its share price prior to the disclosure of CVC’s takeover approach in March. This premium reflects the investors’ optimism about the company’s future prospects and the competitive nature of this acquisition process.

Strategic Rationale Behind the Acquisition

The partnership between CVC and GBL underscores a broader trend in the pharmaceutical industry, where private equity firms are increasingly targeting established companies to harness long-term growth opportunities. Recordati, with its strong portfolio of specialty medicines and robust presence in European markets, is well-positioned to leverage the advantages that this acquisition brings.

Potential Benefits for Recordati

Under the new alliance, Recordati is expected to unlock additional avenues for development and expansion. CVC’s financial acumen, combined with GBL’s strategic insights, aims to enhance Recordati’s capabilities in a rapidly evolving market. Stakeholders are closely monitoring how the integration of these two firms will influence Recordati’s growth trajectory and overall vision.

Investor Confidence in the Pharmaceutical Sector

The commitment demonstrated by CVC and GBL is indicative of robust investor confidence in the future of the pharmaceutical sector. As private equity firms increasingly seek to invest in established companies like Recordati, this acquisition highlights the potential for innovation and advancement within the industry.

Conclusion

As the acquisition unfolds, the collaboration between CVC and GBL is set to reshape Recordati’s future in the pharmaceutical landscape. With a clear focus on enhancing growth and fostering innovation, this partnership not only signifies a new chapter for Recordati but also reflects the evolving dynamics of the investment landscape in the pharmaceutical industry.